caa a22 4500 467945136 CHVBK 20180405193736.0 cr unu---uuuuu 170328e20041101xx s 000 0 eng 10.1007/s10549-004-6006-1 doi (NATIONALLICENCE)springer-10.1007/s10549-004-6006-1 (NATIONALLICENCE)springer-10.1007/s10459-004-6006-2 Expression of FGF-2 alters focal adhesion dynamics in migration-restricted [Elektronische Daten] [Reju Korah, Lydia Choi, Judith Barrios, Robert Wieder] Basic fibroblast growth factor (FGF-2) expression takes place during morphogenic differentiation of mammary ducts and is lost in breast cancer. Forced re-expression of FGF-2 in breast cancer cell lines induces a more differentiated phenotype and inhibits motility by unknown mechanisms. Here we demonstrate that MDA-MB-231 cells with encumbered motility due to forced re-expression of FGF-2 have activated focal complexes as determined by immunoprecipitation/western blotting and immunofluorescence staining with antibodies to FAK, p130Cas, paxillin, vinculin and phosphotyrosine. The activation of the focal adhesion complexes results in loss of stress fibers associated with malignant transformation of mammary epithelial cells and the formation of circumferentially-distributed actin bundles associated with non-transformed mammary epithelial cells. These effects require continuous FGF-2 expression, as the effects of exogenous recombinant FGF-2 are only small and transient. FGF-2 expression results in an increase in integrin α3 expression and decreases in integrin β1 and β4 expression. These changes, however, induce only a small decrease in adhesion to uncoated and fibronectin-coated tissue culture dishes suggesting that the primary cause of impaired motility is due to intrinsic signaling. These data suggest that FGF-2-inhibits motility in breast cancer cells by stabilization of focal complexes and induction of a more differentiated phenotype with disruption of stress fiber formation and a characteristic cortical actin distribution. Kluwer Academic Publishers, 2004 basic fibroblast growth factor nationallicence focal adhesion complex nationallicence F-actin nationallicence breast cancer nationallicence motility nationallicence Korah Reju Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut Choi Lydia Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut Barrios Judith Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut Wieder Robert Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut Breast Cancer Research and Treatment Kluwer Academic Publishers 88/1(2004-11-01), 17-28 0167-6806 88:1<17 2004 88 10549 https://doi.org/10.1007/s10549-004-6006-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10549-004-6006-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Korah Reju Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Choi Lydia Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Barrios Judith Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Wieder Robert Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, MSB I-596, 07103, Newark, NJ, USA aut NATIONALLICENCE 773 0- Breast Cancer Research and Treatment Kluwer Academic Publishers 88/1(2004-11-01), 17-28 0167-6806 88:1<17 2004 88 10549 NATIONALLICENCE 700 1- Korah Reju Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, NJ, USA aut NATIONALLICENCE 700 1- Choi Lydia Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, NJ, USA aut NATIONALLICENCE 700 1- Barrios Judith Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, NJ, USA aut NATIONALLICENCE 700 1- Wieder Robert Department of Medicine, Division of Oncology/Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, NJ, USA aut NATIONALLICENCE 856 40 https://doi.org/10.1007/s10459-004-6006-2 text/html Onlinezugriff via DOI Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 467269858 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE NATIONALLICENCE NL-springer